Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-09-2009 | Preclinical Study

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo

Authors: Rui Wang, Xi Wang, Bin Li, Fang Lin, Ke Dong, Ping Gao, Hui-Zhong Zhang

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

Background Survivin is a member of the inhibitors of apoptosis protein family, is expressed in most of human cancers. Thus, we hypothesized that using a survivin promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to survivin-positive tumor cells. PUMA (p53 upregulated modulator of apoptosis) was recently identified a potent proapoptotic molecule. In the present study, our aim is to investigate whether adenovirus-mediated PUMA gene transfer using the survivin promoter could specifically enhance radiosensitivity of breast cancer cells in vitro and in vivo. Materials and methods Firstly, we performed RT-PCR assay to detect survivin mRNA expression in four human breast cancer cell lines and two normal cell lines. Then, we constructed plasmid vectors expressing luciferase or EGFP reporter gene driven by the survivin core promoter and evaluated its transcriptional activity in vitro. Next, a survivin promoter-driven adenoviral system expressing PUMA gene was constructed. Western blotting analysis of PUMA protein expression in MCF-7 and MCF210 cells treated with various adenovirus (empty, driven by CMV promoter or survivin promoter). Followingly, the effects of PUMA overexpression on the in vitro radiosensitivity of breast cancer cells were investigated by clonogenic formation assay. Cellular apoptosis were determined by FCM and TUNEL assays. The expression and activities of cellular caspase-3 were assayed by Western blot and colorimetry. Finally, we investigated the effect of PUMA overexpression on the radiosensitivity of breast carcinoma cells in vivo. Results The survivin mRNA expression was obviously upregulated in breast cancer cell lines but in normal cell lines. Moreover, the survivin promoter could drive high-level expression of luciferase or EGFP in breast cells but not in normal cells. Using a survivin promoter-driven adenoviral system expressing PUMA gene, we found that PUMA expression was specifically and efficiently induced in MCF-7 cell but not in MCF210 cell. Furthermore, we observed that the novel adenovirus system could significantly enhance radiosensitivity of MCF-7 cell in vitro and in vivo, which might be associated with apoptosis induction by activating cellular caspase-3. Conclusion Our findings indicated that the survivin promoter-driven adenovirus system expression PUMA gene might be explored as a potential tool for radiosensitization of human breast cancer cells with tumor specificity and high efficacy.
Literature
1.
go back to reference WHO World Health Report (2003) World Health Organization, Geneva, 2003 WHO World Health Report (2003) World Health Organization, Geneva, 2003
4.
go back to reference Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK et al (2003) Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353–360PubMed Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK et al (2003) Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353–360PubMed
6.
go back to reference Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C et al (2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63:1490–1499PubMed Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C et al (2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63:1490–1499PubMed
7.
14.
17.
go back to reference Wang H, Qian H, Yu J, Zhang X, Zhang L, Fu M et al (2006) Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther 5:380–385PubMedCrossRef Wang H, Qian H, Yu J, Zhang X, Zhang L, Fu M et al (2006) Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther 5:380–385PubMedCrossRef
20.
go back to reference Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al (2008) Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 15:214–223. doi:10.1038/sj.gt.3303057 PubMedCrossRef Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al (2008) Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 15:214–223. doi:10.​1038/​sj.​gt.​3303057 PubMedCrossRef
21.
go back to reference Cheng ZJ, Hu LH, Fu WR, Zhang Q (2008) Expression of survivin and its splice variants in gastric cancer. Zhonghua Bing Li Xue Za Zhi 37:130–131PubMed Cheng ZJ, Hu LH, Fu WR, Zhang Q (2008) Expression of survivin and its splice variants in gastric cancer. Zhonghua Bing Li Xue Za Zhi 37:130–131PubMed
24.
go back to reference Wu B, Wang Y, Ren JH et al (2005) Molecular cloning of survivin gene promoter and detecting its specific activity in Hela cell. Chin J Cancer Biother 12:116–119 Wu B, Wang Y, Ren JH et al (2005) Molecular cloning of survivin gene promoter and detecting its specific activity in Hela cell. Chin J Cancer Biother 12:116–119
30.
go back to reference Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al (2000) Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359–5364PubMed Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al (2000) Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359–5364PubMed
31.
Metadata
Title
Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo
Authors
Rui Wang
Xi Wang
Bin Li
Fang Lin
Ke Dong
Ping Gao
Hui-Zhong Zhang
Publication date
01-09-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0163-6

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine